← Leaderboards
Hobart H Harris
University Of California San Francisco
$564
Attributed
$564
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$564 · 2
By mechanism
M01$564 · 2
Top collaborators
No co-investigators on record.
Most similar at University Of California San Francisco
Same institution · by research overlap
- Zena Werb$33,582,689
- Susan J. Fisher$38,160,909
- Frank Patrick McCormick$56,513,144
- Judith Ann Aberg$20,303,532
- Matthew G Dorsey$21,862,621
Others in their field
Top investigators on “Human Subject”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- George R Seage · Abt Associates, Inc.$172,422,660
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$160,455,836
- Jeffrey P Krischer · University Of South Florida$155,493,283
- Charles A Coltman · Southwest Oncology Group$154,811,913
Research focus
Human SubjectHuman Therapy EvaluationClinical ResearchVancomycinGram Positive BacteriaMicroorganism Disease ChemotherapyPharmacokineticsSkin InfectionAntibioticsRibonucleotide ReductaseNeoplasm /Cancer ChemotherapyOutcomes ResearchPancreas NeoplasmsDrug Screening /EvaluationGemcitabineTissue Inhibitor Of MetalloproteinasesClinical TrialsBlood Chemistry
Grant awards (7)
LY333328 VS VANCOMYCIN IN SKIN/SKIN STRUCTURE INFECTIONS$0
M01 · FY2002 · RR
LY333328 VS VANCOMYCIN IN SKIN/SKIN STRUCTURE INFECTIONS$0
M01 · FY2002 · RR
LY333328 VS VANCOMYCIN IN SKIN/SKIN STRUCTURE INFECTIONS$0
M01 · FY2001 · RR
EFFICACY AND SAFETY OF MARIMASTAT VS GEMCITABINE FOR TREATMENT OF CANCER$564
M01 · FY2000 · RR
LY333328 VS VANCOMYCIN IN SKIN/SKIN STRUCTURE INFECTIONS$0
M01 · FY2000 · RR
LY333328 VS VANCOMYCIN IN SKIN/SKIN STRUCTURE INFECTIONS$0
M01 · FY2000 · RR
LY333328 VS VANCOMYCIN IN SKIN/SKIN STRUCTURE INFECTIONS$0
M01 · FY2000 · RR